================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 14, 2006
TRANSGENOMIC, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-30975 911789357
-------------- ------------ ----------------------
(State of (Commission (IRS Employer
Incorporation) File Number) Identification Number)
12325 Emmet Street, Omaha, Nebraska 68164
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(402) 452-5400
----------------------------------------------------
(Registrant's telephone number, including area code)
Not applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 14, 2006, Transgenomic, Inc. issued a press release
announcing its financial results for the third quarter of 2006. A copy of the
press release is being furnished herewith as Exhibit 99 to this Current Report
on Form 8-K.
The information referenced in this Current Report on Form 8-K
(including Exhibit 99 referenced in Item 9.01 below) is being `furnished" under
"Item 2.02. Results of Operations and Financial Condition" and, as such, shall
not be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that Section. The information set forth in this Current
Report on Form 8-K (including Exhibit 99 referenced in Item 9.01 below) shall
not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended (the "Securities
Act"), except as shall be expressly set forth by specific reference in such
filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
(99) Press release dated November 14, 2006, announcing
Transgenomic, Inc.'s financial results for the third quarter
of 2006.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: November 14, 2006 TRANSGENOMIC, INC.
By: /s/ Craig J. Tuttle
-------------------------------------
Craig J. Tuttle
President and Chief Executive Officer
3